Zenas BioPharma reported a net loss of $111.5 million for the quarter ended June 30, 2026, compared to a $52.2 million loss in the prior year period. The company holds $673.9 million in cash and investments as of June 30, 2026. Key operational highlights include FDA acceptance of the Biologics License Application for obexelimab for IgG4-RD, establishing a PDUFA target action date of May 27, 2027. The Board appointed Christy J. Oliger as a Class II director effective September 1, 2026, increasing the board size by one. Additionally, CFO Jennifer Fox will transition to Strategic Advisor to the Board Chair on September 30, 2026. Zenas BioPharma is a clinical-stage global biopharmaceutical company advancing therapies for autoimmune and inflammatory diseases.